Lablanche J M, Leroy F, Mc Fadden E P, Bauters C, Bertrand M E
Service de Cardiologie B et Hémodynamique, Hôpital Cardiologique, CHR-Lille, France.
J Cardiovasc Pharmacol. 1992 Sep;20(3):473-8. doi: 10.1097/00005344-199209000-00020.
The coronary vasodilator properties of isosorbide dinitrate are well established but the doses generally used (1,000-2,000 micrograms) are still empirical. We studied, with the use of quantitative coronary arteriography (CAESAR System), the response of smooth vessel segments (greater than 1.85 mm diameter), preconstricted with methylergometrine (400 micrograms i.v.), to intracoronary injections of graded doses (5-100 micrograms) of isosorbide dinitrate and the effects of these injections on systemic hemodynamic parameters in 10 patients undergoing diagnostic coronary angiography. Six further patients, in whom the injections of isosorbide dinitrate were replaced by equivalent volumes of normal saline, served as controls. Relative to the diameter 5 min after injection of methylergometrine, the diameter increased by a mean +/- SD of 9 +/- 7, 26 +/- 12, 33 +/- 15, 38 +/- 14, and 39 +/- 16% after injections of 5, 15, 60, 240, and 1,000 micrograms, respectively, of isosorbide dinitrate. After a cumulative dose of 80 micrograms, subsequent doses did not cause further significant increases in diameter. Injection of saline in the control group did not alter the coronary diameter. A significant fall in systolic arterial pressure, compared to the control group, occurred at a cumulative dose of 320 micrograms. The mean arterial pressure and heart rate were unchanged. Significant coronary vasodilation occurs with intracoronary doses of isosorbide much smaller than those currently employed. Cumulative doses of 320 micrograms or more cause systemic hemodynamic changes without producing additional coronary vasodilation. During interventional cardiac procedures, where systemic hypotension is undesirable, the use of smaller doses of intracoronary isosorbide dinitrate than currently employed may be feasible and should be investigated further.
硝酸异山梨酯的冠状动脉扩张特性已得到充分证实,但通常使用的剂量(1000 - 2000微克)仍属经验性剂量。我们使用定量冠状动脉造影(CAESAR系统),研究了在10例接受诊断性冠状动脉造影的患者中,用甲基麦角新碱(400微克静脉注射)预收缩的直径大于1.85毫米的血管平滑肌段对冠状动脉内注射不同剂量(5 - 100微克)硝酸异山梨酯的反应,以及这些注射对全身血流动力学参数的影响。另外6例患者用等量生理盐水代替硝酸异山梨酯注射作为对照。相对于注射甲基麦角新碱5分钟后的直径,注射5、15、60、240和1000微克硝酸异山梨酯后,直径分别平均增加了9±7%、26±12%、33±15%、38±14%和39±16%。累积剂量达到80微克后,后续剂量不会导致直径进一步显著增加。对照组注射生理盐水未改变冠状动脉直径。与对照组相比,累积剂量达到320微克时,收缩动脉压显著下降。平均动脉压和心率未改变。冠状动脉内注射比目前使用剂量小得多的硝酸异山梨酯就能产生显著的冠状动脉扩张。累积剂量达到320微克或更高时会引起全身血流动力学变化,但不会产生额外的冠状动脉扩张。在介入性心脏手术中,由于不希望出现全身低血压,使用比目前剂量更小的冠状动脉内硝酸异山梨酯可能是可行的,应进一步研究。